Log in with your email address username.

×

Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] Are all drug-eluting stents created equal?

Non-inferiority trials with combined clinical endpoints in allcomer populations were suggested as a compromise between premarket assessments and speed of innovation.1 However, it is important to remain aware of the limitations of the information provided by these trials. In The Lancet, Clemens von Birgelen and colleagues2 report their comparison of two highly regarded drug-eluting stents in clinical use (the Resolute Onyx and the Orsiro stents) in a population of 2488 allcomers. The primary endpoint was target vessel failure, a hierarchical combination of safety endpoints (cardiac death or target vessel myocardial infarction) with an efficacy endpoint (target vessel revascularisation) at 1 year.

email